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The different members of the Bcl-2 family are essential regulators of programmed cell death. These different members share one or more
Bcl-2 homology domains, required for their ability to regulate each other. In this review, we describe current knowledge of the functions of
different Bcl-2 members and their potential roles in disease and immunity.
D 2003 Elsevier B.V. All rights reserved.Keywords: Apoptosis; Bcl-2; BH3-only protein; Regulation; Disease; Immunity1. Introduction
Programmed cell death or apoptosis is essential for
normal development, immune function and tissue homeo-
stasis. Deregulation of apoptosis has been linked to a
number of diseases and in the last decade, our under-
standing of how apoptosis is regulated may help to find
novel ways to treat diseases [1]. Bcl-2 (B cell leukemia/
lymphoma 2), the prototypic member of the Bcl-2 family,
was identified as a result of the t(14;18)(q32;q31) chro-
mosomal translocation in human follicular B cell lympho-
ma inducing its overexpression [2]. Genetic and biochem-
ical studies in different organisms including mammals, D.
melanogaster and C. elegans indicate that proteins of the
Bcl-2 family are critical regulators of apoptosis. However,
how these proteins regulate apoptosis remains controver-
sial. In this review, we will focus on the mammalian
members and discuss their possible involvement in dis-
ease and immunity.2. Bcl-2 family member functions
Bcl-2 is the founding member of a growing family whose
members have emerged as important regulators of cell death.0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2003.10.011
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E-mail address: Dgreen5240@aol.com (D.R. Green).The Bcl-2 family members can have anti- or pro-apoptotic
functions. The anti-apoptotic members namely Bcl-2, Bcl-XL
(a splice variant of the bcl-x gene), Mcl-1, A1/BFL-1, Bcl-w,
Boo/Diva/Bcl-2-L10/Bcl-B and NR13 share three or four
regions of sequence similarity, the Bcl-2 homology (BH)
domains. The pro-apoptotic members can be classified into
two subgroups according to their structures. Bax, Bak, Bok/
Mtd, Bcl-XS (a splice variant of the bcl-x gene) and Bcl-GL
(a splice variant of the bcl-g gene), containing two or three
BH regions, belong to the multidomain (or BH1, 2, 3)
subgroup, whereas Bad, Bid, Bik/Nbk, Bim/Bod, Blk, Hrk/
DP5, Noxa, Puma/Bbc3, Bnip3, Bmf and Bcl-GS (a splice
variant of the bcl-g gene) share with each other the nine amino
acid BH3 domain (Table 1). A curious feature of murine Noxa
is the presence of two BH3 domains, whereas human Noxa
contains a single BH3 region [3], but it is still unclear whether
the second BH3 domain affects Noxa function in mice. BH3
domains appear to be very important regulatory domains
because of their conservation through all the members of this
family. However, their exact functions are still unclear. BH3-
only proteins may directly activate multidomain pro-apopto-
tic members, inactivate the Bcl-2 anti-apoptotic members or
both. Where are all these players acting?
Two distinct pathways of cell death leading to caspase
activation have been reported (Fig. 1): a pathway involving
death receptors and one acting through mitochondria. Inter-
action of a death receptor, such as Fas (CD95) with its
ligand triggers formation of a death-inducing signaling
complex (DISC), including the adaptor molecule FADD,
which in turn recruits procaspase-8. Procaspase-8 is then
Table 1
Sequences of BH3-only domains of several Bcl-2 members
Bcl-2 members BH3-only domains
Anti-apoptotic
hBcl-2 LRQAGDDFS
hBcl-XL LREAGDEFE
hBcl-w MRAAGDEFE
hMcl-1 LRRVGDGVQ
Pro-apoptotic
Bax-like
hBax LKRIGDELD
hBak LAIIGDDIN
hBok/Mtd LLRLGDELE
hBcl-GL LKYSGDQLE
BH3-only
hBad LRRMSDEFV
hBid LAQVGDSMD
hBik/Nbk LACIGDEMD
hBim/Bod LRRIGDEFN
hHrk/DP5 LKAIGDELH
hPuma/bbc3 LRRMADDLN
hBnip3 LKKNSDWIW
hBcl-GS LKYSGDQLE
mNoxa LRKIGDKVY
LRRIGDKVN
mBlk LACIGDEMD
Consensus LRRIGDEFD
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oligomeric recruitment complex, which in turn can activate
other procaspases leading to cleavage of different cellular
substrates [4,5].
The second pathway targets the mitochondria, inducing
the release of cytochrome c. Holocytochrome c then
induces apoptotic protease-activating factor 1 (Apaf-1)
oligomerization that in turn activates caspase-9 without
any requirement for caspase-9 cleavage [6]. This active
cytochrome c/Apaf-1/caspase-9 complex has been called
the ‘‘apoptosome’’ and initiates effector caspases such as
caspases 3 and 7 [7]. However, the mechanisms by which
cellular stress or other signals activate the mitochondrial
cell death pathway are poorly understood and is still
under investigation.
Crosstalk between these two pathways commonly
occurs. For example, Fas-dependent activated caspase-
8 cleaves the inactive p22 Bid member within an un-
structured loop [8–10], which exposes a glycine that is
N-myristoylated [11]. This p7/myr-p15 Bid form targets
mitochondria, where it activates the multidomain pro-
apoptotic members Bax and Bak to induce caspase
activation through mitochondrial protein release [12,13]
as described above. In many cells, the crosstalk seems to
be necessary for the efficient activation of downstream
caspases and serves as an amplifier on the way to cell
death.
Mitochondrial cytochrome c release is regulated through
interactions between various pro- and anti-apoptotic Bcl-2
members. But what are the functional forms of Bcl-2members: monomers, homodimers, heterodimers, homo-
multimers or heteromultimers? And what are the critical
partners in vivo? The pro-apoptotic proteins, Bax, originally
discovered as a protein that coimmunoprecipitated with Bcl-
2 [14], and Bak are present as inactive monomers in cells in
the absence of apoptotic stimuli [15]. Upon activation, Bax
is induced to oligomerize and migrate to the mitochondria
[16] while Bak, already residing at mitochondria, is also
homo-oligomerized into higher order multimers [12]. Re-
cent data suggest that Bcl-2 or Bcl-XL anti-apoptotic mem-
bers sequester BH3 domain-only proteins in stable
mitochondrial complexes, preventing Bax and Bak activa-
tion [17,18]. However, Bax does not homodimerize or
heterodimerize with Bcl-XL in the absence of detergent,
indicating that the BH3 domain of Bax may be inaccessible
under physiological conditions [19,20]. A recent report on
the tertiary structure of Bax suggests that its BH3 domain,
required for heterodimerization with Bcl-XL and Bcl-w may
not be exposed for such interactions [21]. The above
observations raised questions as to the extent to which
Bax heterodimer and homodimer formation occur under
physiological conditions in the absence of a pro-apoptotic
signal.
How Bcl-2 family proteins regulate mitochondrial outer
membrane permeability is controversial and several mech-
anisms have been proposed to account for mitochondrial
membrane permeabilization. A first step involves pore
formation in the external mitochondrial membrane involv-
ing Bax oligomerization and the truncated Bid protein
[16,22]. Two general models have been proposed for what
happens next. In Model 1, this first event alters the
integrity of the mitochondria by inducing changes in
mitochondrial function such that: (i) the adenine nucleo-
tide transporter (ANT) localized in the inner membrane
opens and induces matrix swelling and outer mitochon-
drial membrane disruption [23] or (ii) the voltage-depen-
dent anion channel (VDAC) in the outer membrane
closes, resulting in inner membrane dysfunction that
induces matrix swelling and outer mitochondrial mem-
brane disruption [24]. In Model 2, the oligomerized
multidomain pro-apoptotic molecules cause pore-forma-
tion in the outer membrane without involving the inner
membrane, inducing mitochondrial protein release [13,25].
In agreement with this last model, such release was
recently shown to be mediated by supramolecular open-
ings in the outer mitochondrial membrane, involving
BH3/Bax/lipid interaction, directly inhibited by Bcl-XL,
without any requirement for the mitochondrial inner
membrane or proteins in the outer membrane [26].3. Lessons from the analysis of transgenic mice and gene
invalidation
One important method for studying the functional
effects of specific gene products in vivo is the creation
Fig. 1. Cell death pathways. Trimeric death ligands bind their receptors to trigger an intracellular cascade leading to apoptosis. The active dimeric caspase-8
then either cleaves executioner procaspases (such as capases-3 and-7) or cleaves the BH3-only protein Bid, which translocates to the mitochondria after
myrostylation. Bid triggers Bax/Bak multidomain subfamily proteins to induce the release of mitochondrial proteins such as cytochrome c. Alternatively, stress-
induced signals are directly transduced to the mitochondria by acting on BH3-only proteins activating in turn Bax/Bak multidomain members leading to
cytochrome c release. Cytochrome c promotes the formation of an apoptosome that activates procaspase-9, which in turn activates executioner caspases to
orchestrate apoptosis.
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defined tissue. For instance, lymphoid promoters and
enhancers were used to overexpress Bcl-2 in lymphocytes.
In mice expressing an El-bcl-2 transgene within the T
lymphoid compartment, T cells resisted killing by lym-
photoxic agents [27] and transgenic mice that overexpress
Bcl-2 in their B cells progress to high-grade lymphomas
[28,29]. Accordingly, the Bcl-2 protein is found overex-
pressed in various lymphomas, acute leukemias and
several types of human solid tumors [30]. Transgenic
overexpression of A1 in T cells via the lck promoter
resulted in decreased apoptosis following activation and
led to a doubling of T cell yield by 5 days [31]. In the
same way, transgenic overexpression of Bcl-XL within the
T cell compartment resulted in resistance to apoptosis
induced by glucocorticoid, g-radiation and CD3 cross-
linking [32]. These data suggest that transgenic Bcl-2, A1
or Bcl-XL overexpression can reduce apoptosis in resting
and activated T cells. Transgenic overexpression of Bcl-
XL in megakaryocytes via the platelet factor 4 (PF4)
promoter displayed poorly developed platelet demarcation
membranes and cell margin extensions, suggesting that
Bcl-XL expression is important for megakaryocyte devel-
opment [33]. Interestingly, transgenic mice bearing a
human bcl-2 or a human bcl-x transgene under the control
of the promoter of the murine housekeeping phospho-
glycerate kinase-1 (pgk-1) gene express high levels of theBcl-XL or Bcl-2 proteins in the male germinal cells and
show a highly abnormal adult spermatogenesis accompa-
nied by sterility [34]. All together, these studies show that
regulated expression of different anti-apoptotic members
of the Bcl-2 family is important for the development of
different cell types.
To identify the functions of different Bcl-2 members,
gene-ablating technologies were developed in mice. Knock-
out mice lacking functional genes have provided extensive
information about the roles of Bcl-2 members in the
immune system and during development. Table 2 summa-
rizes the different phenotypes obtained from these studies.
However, a limitation of current gene targeting technolo-
gies in mice is a difficulty in interpreting the absence of a
phenotype when ablating the function of a single gene.
Indeed, little or no cell death phenotype in some cases
may be explained by functional redundancy or compen-
sation among members of multigene families such as the
Bcl-2 family. For example, Bax-deficient mice proved
viable and showed increased thymocytes (1.6-fold) and
B cells [35]. Sympathetic neurons from Bax-deficient
animals are resistant to cell death upon trophic factor
deprivation [36]. In addition, the apoptosis and thymic
hypoplasia occurring in Bcl-2-deficient mice is prevented
by deletion of Bax, arguing that Bcl-2 functions to inhibit
Bax in thymocytes [37]. In the same way, Bak-deficient
mice are found to be developmentally normal and assays
Table 2
Phenotypes of different Bcl-2 member-deficient mice
Bcl-2
members
Knock-out
phenotypes
Anti
Bcl-2 defect in renal
development
[103,104]
premature loss of
lymphoid cells inducing
immunodeficiency
loss of hair pigmentation
due to loss of melanocytes
Bcl-XL die during embryogenesis
with massive increase in
apoptosis in developing
postmitotic cells of dorsal
root ganglia, brain stem
and the embryonic
spinal cord
[105]
Bcl-w viable, healthy and normal
in appearance
[106]
males are infertile
Mcl-1 peri-implantation
embryonic lethality
[107]
A1-a spontaneous apoptosis of
peripheral blood
neutrophils
[108,109]
diminution of acute
inflammatory response
Diva no obvious histological
abnormalities
[110]
Pro
Bax-like
Bax viable, increased number
of thymocytes and B cells
[35]
sympathetic neurons are
resistant to cell death upon
trophic factor deprivation
Bak developmentally normal [38]
Bax/Bak die perinatally due to
multiple developmental
defects
[38]
BH3-only
Bid hepatocytes are resistant
to Fas-induced apoptosis,
whereas lymphocytes
are normally sensitive to
Fas-treatment
[42]
development of a
myeloproliferative
disorder
[43]
Bim increased numbers of
lymphoid and myeloid
cells
[40]
inhibition of loss of
autoreactive thymocytes
promoted by
superantigen as well as
by peptide
[41]
thymocytes are refractory
to apoptosis induced by
TCR-CD3 stimulation
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apoptotic stimuli revealed no differences in comparison to
wild-type controls [38]. These data suggest that multi-
domain pro-apoptotic Bcl-2 family members such as Bax
and Bak may serve redundant functions in the regulation
of cell death. Confirming this notion, the majority of
bax /bak / animals die perinatally due to multiple
developmental defects [38]. Cells doubly deficient in bax
and bak are profoundly resistant to multiple apoptotic
stimuli, indicating that Bax and Bak act upstream in the
mitochondrial pathway of apoptosis [13]. However, the
ability of bax /bak / thymocytes to initiate apoptosis
in response to Fas signal transduction is comparable to
that of wild-type thymocytes, suggesting that at least in
some tissues, cell death can be induced in the absence of
both Bax and Bak, via the death receptor pathway
discussed above [38].
Is there a Bcl-2 family member that can replace Bax and
Bak? Because Bok is homologous to Bax and Bak in BH
domain arrangement and secondary structure, the Bok
protein could be a good candidate to functionally replace
Bax and Bak in their absence. But, unlike several pro-
apoptotic Bcl-2 proteins, Bok does not interact with Bcl-2
and Bcl-XL but preferentially dimerizes with anti-apoptotic
members Mcl-1 and A1, arguing a different mechanism
[39]. The mechanism by which Bok promotes cell death
remains unknown and future experiments are necessary to
understand its real involvement during apoptosis.
Gene targeting experiments have also begun to dissect
the function of these different members in mammals in
spite of a higher level of complexity due to the existence
of at least eight different BH3-only proteins. The only
knock-out experiments of BH3-only proteins reported so
far involve Bim and Bid. Bim-deficient mice have in-
creased numbers of lymphoid and myeloid cells, whereas
numbers of erythrocytes and megakaryocytes are un-
changed [40]. Bim / lymphocytes are resistant to certain
apoptotic stimuli such as cytokine deprivation, calcium
ion flux and microtubule perturbation but are sensitive to
DNA damage or glucocorticoids [40]. The loss of autor-
eactive thymocytes promoted by superantigen as well as
by peptide is inhibited in Bim-deficient mice and Bim /
thymocytes are refractory to apoptosis induced by TCR-
CD3 stimulation [41]. Thus, activation of Bim is a
primary signal for negative selection of autoreactive T
cells during their development in the thymus. Bid-defi-
cient mice appear normal and their hepatocytes are
resistant to Fas-induced apoptosis whereas their lympho-
cytes are normally sensitive to Fas-treatment [42]. More
recently, Bid-deficient mice, as they age, were shown to
spontaneously develop a myeloproliferative disorder, pro-
gressing from myeloid hyperplasia to a fatal, clonal
malignancy similar to chronic myelomonocytic leukemia
(CMML) [43]. These data implicate Bid in regulating
homeostasis of the myeloid compartment derived from
long-term repopulating cells.
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be also used to try to dissect apoptotic pathways in
human cell lines. For example, Puma-deficient HCT116
cells, having an intact p53 pathway, are highly resistant to
hypoxia- and DNA-damaging drug-induced apoptosis
[44]. On the other hand, we recently showed that Noxa
can contribute to p53-dependent apoptosis by using RNA
interference to knock down endogenous Noxa RNA
expression in MEF cells [45]. All together, these data
suggest that in different cell types, different stimuli may
require different BH3-only proteins to induce apoptosis.
Future generation and analysis of mice lacking individual
BH3-only proteins or combinations of these members will
help to elucidate their mechanism during animal develop-
ment and apoptosis regulation.4. Subtle regulation of Bcl-2 family members at several
levels
Regulation of the activities of Bcl-2 proteins is com-
plex and includes both transcriptional and post-transla-
tional mechanisms. Activation of p53 in response to
cellular or genotoxic stress induces several responses,
including differentiation, senescence, DNA repair, cell-
cycle arrest and apoptosis. It seems likely that the
activation of p53-dependent apoptosis can contribute to
the inhibition of cancer development at several stages
during tumorigenesis [46]. The best understood function
of p53 is its transcriptional activation of target genes.
Among all the different p53 target genes, several mem-
bers of the Bcl-2 family were identified in response to
DNA damage, including Bax, Puma, Noxa and more
recently Bid (Table 3) [3,47–51]. However, the bax gene
promoter is only weakly bound by p53 in certain cells
compared for example with puma promoter, excluding
bax as a major target of p53 in this case [52]. In fact, no
single target gene has been found to be required for the
full response during apoptosis, arguing in favor of a
coordinate effect of activation of several genes. Together,
these results suggest that Bcl-2 member target genes for
p53 may be functionally important in the cellular re-
sponse to treatment with chemotherapeutic agents.Table 3
p53-responsive element sequences in some Bcl-2 member promoters
Bcl-2 member known as p53 target
Member p53 binding sequence into the promoter
Murine
Bax
Puma
Noxa 5V-AGGCTTGCCCcGGCAAGTTG-3V
Bid 5V-GGCATGTCCTGGCTAGTTT-3V
Consensusa 5V-RRRCWWGYYYRRRCWWGYYY-3V
a Where R denotes A or G, W denotes A or T and Y denotes C or T.Relatively little is known about the regulation of Bcl-2
family genes at the promoter level and the transcription
factors that regulate them. Two promoter regions have been
identified in the 5V-regulatory region of the bcl-2 gene. P1,
the predominant promoter in B cells, is a TATA-less
promoter, whereas P2 localized 1.3 kilobase pairs down-
stream of P1, contains a CCAAT box and a TATA element
[53,54]. The Wilms’ tumor gene (WT1), sharing 64%
homology to the zinc fingers of the early growth response
gene 1 (Egr-1), has previously been shown to bind to two
different sites on the bcl-2 P1 promoter [55], whereas
nuclear factor-kappa B (NF-nB) has recently been shown
to bind to the bcl-2 P2 promoter via kappa-B sites [56,57].
NF-nB also regulates A1/Bfl-1 expression in response to
TNF or LPS [58,59]. Hrk/dp5 and bim genes can be
transcriptionally induced by AP-1 [60,61] and the bax
promoter possesses two canonical E-box elements binding
c-Myc/Max heterodimers, suggesting myc-dependent acti-
vation [62]. Several papers have also implicated members of
the Ets, Rel/NF-nB, STAT and AP-1 families as transcrip-
tion factors regulating bcl-xL gene expression [63].
Another form of transcriptional regulation of Bcl-2
family members expression is by alternative splicing. With-
in the Bcl-2 family, splicing variants have been reported for
bcl-2, bcl-x, a1, mcl-1, bcl-w, bak, bax, bok, bnip3, puma,
bcl-g and bim genes. In some cases, variants from the same
gene may exhibit different biological functions. For exam-
ple, the bcl-x gene encodes three different variants, each
with a distinct function; the long form of Bcl-X (Bcl-XL)
exhibits anti-apoptotic activity, whereas Bcl-X-short and
Bcl-X-h are pro-apoptotic [64,65]. The bax gene has also
been shown to encode splice variants. Six different isoforms
of BAX have so far been characterized including BAX-a
[14] that encodes for a 21-kDa protein; BAX-h [14] that
encodes for a 24-kDa protein lacking the carboxy-terminal
part due to a stop codon within the coding region of intron
5; BAX-g [14] which is missing exon 2 resulting in a
protein that prematurely terminates in exon 3; BAX-y [66]
that is missing exon 3 but retains the same translational
frame, the BH1 and BH2 domains and the putative trans-
membrane domain; BAX-N [67] with no putative trans-
membrane domain and, more recently, BAX-j [68] that
contains BH3, BH1 and BH2 domains, putative alpha-5 andHuman References
5V-tcACAAGTTaGAGACAAGCCT-3V [47]
5V-ctcCTTGCCTtGGGCTAGgCC-3V [48]
5V-ctGCAAGTCCtGACTTGTCC-3V
[3]
5V-GGGCATGaTgGtGCATGCCT-3V [51]
5V-RRRCWWGYYYRRRCWWGYYY-3V
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membrane domain but lacks amino acids 159–171 com-
pared to BAX-a. However, the function of all these
alternatively spliced variants is not yet known. Three iso-
forms of Bim were originally characterized: BimEL, BimL
and BimS, differing from each other in cytotoxicity [69].
BimS, the most potent, has been only recently detected in
293 human embryonic kidney cells while BimEL and BimL
have been found in a variety of tissues and cell types
[60,70]. To increase the level of complexity, six new splice
variants of Bim were identified in human cells, including a
number of nonapoptotic splice variants [71,72]. BimAD,
encoding a truncated protein due to a premature stop codon,
induces apoptosis through direct interaction with Bax as
well as through interaction with Bcl-2 and Bcl-XL [72].
Splice variant expression depends on the tissue or the cell
line examined, suggesting that the physiological role of the
various isoforms in modulating apoptotic pathways might
be highly tissue-specific. However, the biological signifi-
cance of Bcl-2 family isoforms remains unclear.
The activities of mammalian Bcl-2 members can also be
regulated post-translationally through proteolysis, myristoy-
lation, phosphorylation, deamidation or sequestration. Bid
can be proteolytically processed by calpain [73,74], gran-
zyme B [75] and caspase-8 [8,9]. Cleavage by caspase-8 but
not granzyme B generates a p15 fragment with an exposed
myristoylation site enhancing its targeting to mitochondrial
membranes and increasing apoptotic potency [11], as de-
scribed above. Recent studies also indicate that, during
apoptosis, activated caspases cleave the N-terminal BH4
domain of anti-apoptotic Bcl-2 and Bcl-XL to yield truncat-
ed molecules resembling the multidomain pro-apoptotic
Bax, Bak or Bok in terms of the BH domain arrangement
[76,77]. These may then promote apoptosis.
Recent reports have demonstrated that the phosphoryla-
tion of different Bcl-2 family members may regulate their
functions. For example, c-Jun N-terminal kinase 1 (JNK1)
can phosphorylate Bcl-2 at least at serine 70 [78–80].
However, the precise function of Bcl-2 phosphorylation is
not completely clear. Indeed, Bcl-2 phosphorylation was
reported to maintain its anti-apoptotic function [78] or by
contrast to inactivate its function [79,80]. Bcl-2 inactivation
by a microtubule-damaging agent such as paclitaxel is
thought to occur when Bcl-2 is phosphorylated at two other
residues, threonine 69 and serine 87, in addition to serine 70
[79,80]. Thus, one explanation could be that multiple-site
phosphorylation may differ functionally from serine 70
mono-site phosphorylation to regulate Bcl-2 anti-apoptotic
function. Bad is also phosphorylated at several serine
residues by different kinases, leading to its inactivation by
sequestration by 14–3–3 scaffold proteins [81]. Intriguing-
ly, Bax interacts with 14–3–3 scaffold proteins without any
phosphorylation requirement [82], increasing the level of
complexity since different signals regulate Bad and Bax
interaction with 14–3–3 scaffold proteins. Recently, Bid
was found phosphorylated at serine 61 and serine 64residues by casein kinase I or II, diminishing its cleavage
by caspase-8 [83]. Opposite to the case of Bad, the BH3-
only protein Bik can be regulated by phosphorylation on
threonine 33 and serine 35 residues by a casein kinase II-
related enzyme, increasing its pro-apoptotic potency [84].
However, one more mystery is how Bik is held inactive in
unstimulated cells since casein kinase II is ubiquitously
expressed [83].
A new mechanism of Bcl-2 family regulation was
recently reported, that of deamidation. Deamidation is a
post-translational modification in which asparagines are
converted to a mixture of aspartates and isoaspartates [85].
Treatment of several types of tumor cells with DNA-
damaging agents induces deamidation of two asparagines
(asparagine 52 and 66 residues) in the unstructured loop of
Bcl-XL [86]. This deamidation appears to affect the anti-
apoptotic activity of Bcl-XL by disrupting its ability to block
the pro-apoptotic activity of BH3-only proteins.
In normal cells, the BH3 only proteins Bim and Bmf
are sequestered in motor complexes that interact with the
cytoskeleton. Exposure of cells to apoptotic stimuli causes
dissociation of Bim from dynein motor complexes and
Bmf from myosin V motor complexes [87,88]. However,
how these molecules are released is still under investiga-
tion. Bim and Bmf were recently reported to be phos-
phorylated by JNK, leading to their release from the
motor complexes [89]. Using a protein–protein screen,
FKBP38, a member of the immunophilin family, was
recently reported to interact with Bcl-2 and Bcl-XL [90].
FKBP38, an inhibitor of calcineurin, promotes targeting
or insertion of Bcl-2 into mitochondria, thereby assisting
Bcl-2 in its anti-apoptotic function [90]. It remains
unclear if FKBP38 directly chaperones Bcl-2/Bcl-XL to
mitochondria or induces their insertion into the outer
mitochondrial membrane, or both.
BH3-only proteins bind to a groove formed by the
BH1 and BH2 domains on the surface of anti-apoptotic
Bcl-2 family members thanks to their a-helical BH3
domain. Thus, substitution of conserved residues in the
BH3 domain of Bok-L abolishes its ability to dimerize
with anti-apoptotic proteins [91]. Similarly, truncation of
the conserved BH3 domain occurring naturally in Bok-S,
a Bok splice variant, also disrupts heterodimerization but
surprisingly retains cell killing activity, arguing that the
BH3 domain is dispensable for apoptosis induction [91].
BH3 peptides derived from Bax, Bad, Bik or Noxa were
shown to act mainly by interfering with the interaction
between multidomain pro-apoptotic proteins and the anti-
apoptotic proteins Bcl-2 and Bcl-XL [92,93]. These obser-
vations show that these BH3 peptides disrupt the inter-
action with anti-apoptotic members by occupying their
surface pocket and are not sufficient to induce Bax/Bak
activation. On the other hand, BH3 peptides derived from
Bid and Bim induced cytochrome c release similar to
myristoylated BID [92]. Together, these studies may
reveal two different classes of BH3 domains: (i) Bid-like
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Bak proteins, and (ii) Bad-like domains sensitizing mito-
chondria for apoptosis by occupying the pocket of anti-
apoptotic members. Thus, agents that mimic BH3-only
proteins would be predicted to induce cell death and
represent an attractive target for drug design. Recently,
several groups have successfully reported the discovery of
compounds that may mimic BH3 domains (for review, see
Ref. [94]).5. Bcl-2 proteins as prognostic indicators
The prognostic value of different Bcl-2 family mem-
bers is still not very well documented. However, a
number of studies have shown correlations between Bcl-
2 expression and hematological malignancies, including
follicular lymphomas, chronic lymphocytic and acute
myelogenous leukemias [95]. An increase in Mcl-1 ex-
pression was found to be associated with the relapse of
acute myelogenous leukemias and acute lymphocytic
leukemias [96]. Similarly, Bcl-XL expression is activated
by retroviral insertions in some murine T cell leukemias
and lymphomas [97]. However, the fact that these corre-
lations were not confirmed in all cases, may be explained
by possible redundancies between these family members.
In addition, an increase in Bax expression was associated
with unfavorable prognostic outcome in childhood acute
lymphocytic leukemias [98], which is surprising since
Bax-deficient primary pre-B cells are resistant to the
apoptotic effects of Myc and Bax loss accelerates lym-
phoma development in EA-myc transgenics in a dose-
dependent fashion [99]. Bcl-2 and Myc have been shown
to cooperate in transformation [100,101] and EA-myc/EA-
bcl-2 double transgenic mice develop an aggressive and
rapid lymphoma composed of primitive lymphoid cells
[102]. Thus, overexpression of Bcl-2 blocks Myc-induced
apoptosis and alters the differentiation of the lymphoid
cell, while Bax loss alters the sensitivity to Myc-induced
apoptosis without overtly affecting B cell differentiation.
Therefore, the poor prognosis indicated by increase in
Bax may reflect strong anti-apoptotic conditions that are
not affect by increased Bax.6. Conclusions and perspectives
It will be important in the next decade to determine
which of the mechanisms that have been discovered under
overexpression conditions are significant under physiolog-
ical conditions. It will be challenging to further define the
transcriptional and post-translational control mechanisms
that regulate the in vivo activity of different Bcl-2 family
members. Generation of new tools to ‘‘knock-in’’ sequences
that are important for Bcl-2 member regulation will provide
important tests of our ideas (e.g. mutations in sites forphosphorylation, myristoylation, deamidation, caspase
cleavage).
In addition, it is now established that BH3-only proteins
are essential initiators of apoptosis. However, few of these
members have been analyzed in knock-outs. Future experi-
ments with single or multiple gene knock-out mice will
determine which BH3-only proteins are important in which
developmental cell deaths. Since mammalian cells express
multiple Bcl-2 family members, it is currently an enormous
challenge to develop specific tools to elucidate the mode of
action of all these members.
Mutations in different Bcl-2 proteins may also be
pathogenic as discussed above. It will be interesting to
know if mutations in BH3-only genes are responsible for
human disease. Finally, further studies will lead to the
development of compounds that mimic or activate pro-
apoptotic Bcl-2 family members for treatment of autoim-
mune diseases or cancer, or that inhibit BH3-only protein
function to relieve degenerative diseases. There are, how-
ever, practical limitations to developing BH3 mimetics or
inhibitors at the current time, due to the limited biophys-
ical studies on the interactions between the BH3-only
proteins and prosurvival or pro-apoptotic multidomain
Bcl-2 members.References
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